"$26.4 billion was invested in the drug industry last
year, the largest part of which went to discover treatments for cancer."
The brand new report from visiongain has just been
released. "Cancer 2002" is written by visiongain's leading Pharma
Analyst, Daniel Guns and delivers a comprehensive analysis of the current cancer
market. The report focuses on the oncology market as a whole, looking at growth
factors, class dominance and R&D focus.
"There are currently more new drugs in development
for the treatment of cancer than there are cancer indications". Many
anti-cancer drugs and therapies are as well known for the associated side
effects as their therapeutic benefit. These instantly recognisable side effects
can necessitate reduction of dosage of a drug, and can have a serious effect on
the well-being of patients. New cancer drug delivery systems are in development
to minimise harm to non-cancerous cells, whist enhancing the effect on the
tumour itself.
This report delivers:
- Accurate and up-to-date R&D information on the
focus and direction of the major players in oncology
- Identification of the unmet needs in cancer, across
specific disease indications, drug classes and product pipelines
- Profiles of the major players in terms of oncology
focus, investment, company revenues and licensing strategies
Cancer is recognized as the second most common cause of
death in the developed world, and can arise as a result of a number of factors.
The multifactorial nature of cancer breeds a wealth of potential target genes,
enzymes, proteins and hormones. This means that at any one time, there can be
more new drugs in development than types of cancer itself.
View Cart
